Need help finding what you are looking for?
Contact Us
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1745103
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1745103
HLA Typing Market by Technology (PCR, Sequencing ), Product, Application, End User Global Forecasts to 2030
PUBLISHED:
PAGES: 267 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global HLA typing market is projected to grow from USD 1.7 billion in 2025 to USD 2.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2025 to 2030. Transplantation continues to be the preferred treatment option for many patients suffering from chronic dialysis-dependent end-stage renal disease, as well as those requiring heart, liver, or bone marrow transplants. Over the past decade, significant advancements have been made in HLA typing technologies, antibody monitoring, diagnostic methods, and specialized software developed by various companies. These innovations have become integral to the organ transplantation process, enhancing precision and reliability, and have played a key role in driving the expansion of the HLA typing market.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Technology, Product & Service, Application, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
The commercial service providers segment accounted for the highest growth rate in the HLA typing market, by product and service, during the forecast period.
Based on end-user segmentation, the HLA (Human Leukocyte Antigen) typing market is categorized into commercial service providers, hospitals and transplant centers, and research laboratories and academic institutions. Among these, commercial service providers generated the highest revenue and are expected to witness strong growth, driven by the global rise in organ and stem cell transplants, which require precise, high-throughput HLA typing for effective donor-recipient matching. Growing awareness of personalized medicine, advancements in molecular diagnostics, and the increasing adoption of next-generation sequencing (NGS) technologies are key factors fueling demand for more specialized reagents and kits.
.
The diagnostic applications segment held the largest market share in 2024.
The HLA typing market is categorized based on application into diagnostic applications-including donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, and other diagnostic uses-and research applications. The diagnostic application segment is projected to dominate the market throughout the forecast period, with infectious disease testing accounting for the largest share within this segment. This is largely due to the heightened risk transplant recipients face of acquiring infections from donors. Current donor epidemiological screening methods and laboratory diagnostics have limitations in accurately assessing these risks, making infectious disease testing a critical and continuously growing focus area within the diagnostic segment of the transplant diagnostics market.
The market in the North America region is expected to hold a significant market share for the HLA typing market in 2023.
The HLA typing market spans five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, the market is experiencing strong growth driven by the increasing demand for organ and stem cell transplants, the rising prevalence of chronic and autoimmune diseases, and the adoption of advanced molecular diagnostic techniques. This growth is further supported by a well-established healthcare infrastructure, government initiatives such as the National Marrow Donor Program, and greater public awareness of the importance of accurate HLA matching. The region is a hub for innovation and research, with many leading companies in the HLA typing space headquartered in the region. As a result, cutting-edge technologies, including next-generation sequencing (NGS), are being rapidly adopted, further fueling market expansion.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side: 60% and Demand Side: 40%
- By Designation: Managers: 20%, CXOs & Directors: 30%, and Executives: 50%
- By Region: North America: 40%, Europe: 30%, Asia Pacific: 20%, Latin America: 5%, and Middle East & Africa: 5%
List of Key Companies Profiled in the Report
The prominent players in the HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F. Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), Alpha Biotech Limited (Israel), Bag Diagnostics GmbH (Germany), Caredx, Inc. (US), Creative Biolabs (US), Fujirebio Holdings Inc (Japan), Gendx (Netherlands), Hologic, Inc. (US), Histogenetics LLC (US), Hansa Biopharma AB (Sweden), Illumina, Inc. (US), Inno-Train Diagnostik GmbH (Germany), Immucor, Inc. (US), Krishgen Biosystems (India), Omixon Inc. (Hungary), PacBio (US), Proimmune Ltd (UK), Pacific Bioscience of California Inc. (US), TBG Diagnostics Limited (Australia), and Takara Bio Inc. (Japan), among others.
Research Coverage
This report studies the HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to buy this report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall HLA typing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (growing number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding for research activities, growing prevalence of infectious diseases), restraints (high cost of HLA typing products, limited reimbursements for target procedures), opportunities (rising adoption of cross-matching and chimerism testing procedures, growing awareness of organ donations), and challenges (limited number of organ donations and long waiting lists for transplantations, shortage of skilled professionals)
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the HLA typing market
- Market Development: Comprehensive information about lucrative markets
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HLA typing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the HLA typing market.
Product Code: MD 7576
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Indicative list of secondary sources
- 2.1.1.2 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Primary sources
- 2.1.2.2 Key data from primary sources
- 2.1.2.3 Key industry insights
- 2.1.2.4 Breakdown of primary interviews
- 2.1.1 SECONDARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
- 2.2.2 END-USER-BASED MAPPING MARKET ESTIMATION
- 2.3 GROWTH FORECASTING MODEL
- 2.4 DATA TRIANGULATION AND MARKET BREAKDOWN
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 HLA TYPING MARKET OVERVIEW
- 4.2 REGIONAL SNAPSHOT OF HLA TYPING MARKET
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Rising number of organ transplantation procedures
- 5.2.1.2 Increasing technological advancements in sanger sequencing
- 5.2.1.3 Growing funding and research activities
- 5.2.1.4 Increasing prevalence of infectious and autoimmune diseases
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of hla typing products
- 5.2.2.2 Limited reimbursement policies
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Adoption of cross-matching and chimerism testing
- 5.2.3.2 Growth opportunities in emerging markets
- 5.2.4 CHALLENGES
- 5.2.4.1 Shortage of skilled professionals
- 5.2.4.2 Lack of standardization across laboratories
- 5.2.1 DRIVERS
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE, BY INSTRUMENTS
- 5.4.2 AVERAGE SELLING PRICE, BY REAGENTS
- 5.4.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS
- 5.4.4 AVERAGE SELLING PRICE TREND, BY REGION
- 5.5 VALUE CHAIN ANALYSIS
- 5.5.1 R&D
- 5.5.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
- 5.5.3 MARKETING, SALES, AND DISTRIBUTION
- 5.5.4 POST-SALES SERVICES
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.6.1 PROMINENT COMPANIES
- 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
- 5.6.3 END USERS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.1.1 Sequence-based typing
- 5.9.1.2 Next-generation sequencing
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Sample preparation & dna extraction technologies
- 5.9.2.2 Bioinformatics and data analysis software
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Transplant diagnostics
- 5.9.1 KEY TECHNOLOGIES
- 5.10 PATENT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 IMPORT SCENARIO (HS CODE 3822)
- 5.11.2 EXPORT SCENARIO (HS CODE 3822)
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.13 CASE STUDY ANALYSIS
- 5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY GUIDELINES
- 5.14.1.1 North America
- 5.14.1.1.1 US
- 5.14.1.1.2 Canada
- 5.14.1.2 Europe
- 5.14.1.2.1 UK
- 5.14.1.2.2 France
- 5.14.1.2.3 Germany
- 5.14.1.3 Asia pacific
- 5.14.1.3.1 China
- 5.14.1.3.2 Japan
- 5.14.1.3.3 India
- 5.14.1.4 Latin America
- 5.14.1.4.1 Brazil
- 5.14.1.4.2 Mexico
- 5.14.1.5 Middle East & Africa
- 5.14.1.1 North America
- 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.14.1 REGULATORY GUIDELINES
- 5.15 PORTER'S FIVE FORCE ANALYSIS
- 5.15.1 BARGAINING POWER OF SUPPLIERS
- 5.15.2 BARGAINING POWER OF BUYERS
- 5.15.3 THREAT OF NEW ENTRANTS
- 5.15.4 THREAT OF SUBSTITUTES
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.16.2 KEY BUYING CRITERIA
- 5.17 UNMET NEEDS
- 5.18 IMPACT OF AI ON HLA TYPING MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE TRANSPLANT EVALUATION
- 5.18.3 AI USE CASES
- 5.18.4 KEY COMPANIES IMPLEMENTING AI
- 5.19 IMPACT OF 2025 US TARIFF
- 5.19.1 INTRODUCTION
- 5.19.2 KEY TARIFF RATES
- 5.19.3 PRICE IMPACT ANALYSIS
- 5.19.4 IMPACT ON COUNTRY/REGION
- 5.19.4.1 Us
- 5.19.4.2 Europe
- 5.19.4.3 Asia pacific
- 5.19.5 IMPACT ON END-USE INDUSTRIES
6 HLA TYPING MARKET, BY PRODUCT & SERVICE
- 6.1 INTRODUCTION
- 6.2 REAGENTS & CONSUMABLES
- 6.2.1 INCREASED DEMAND FOR SPECIALIZED CONSUMABLES TO DRIVE MARKET
- 6.3 INSTRUMENTS
- 6.3.1 NEED FOR DONOR-RECIPIENT MATCHING AND IMMUNOGENETIC RESEARCH TO AID GROWTH
- 6.4 SOFTWARE & SERVICES
- 6.4.1 GROWING DEMAND FOR ADVANCED AND USER-FRIENDLY SOFTWARE TO BOOST MARKET
7 HLA TYPING MARKET, BY TECHNOLOGY
- 7.1 INTRODUCTION
- 7.2 MOLECULAR ASSAY TECHNOLOGIES
- 7.2.1 PCR-BASED MOLECULAR ASSAYS
- 7.2.1.1 Sequence-specific primer-PCR
- 7.2.1.1.1 Higher speed, precision, and affordability to favor growth
- 7.2.1.2 Sequence-specific oligonucleotide-PCR
- 7.2.1.2.1 Growing applications of PCR in donor-recipient matching, cancer, rheumatoid, and arthritis to drive market
- 7.2.1.3 Real-time PCR
- 7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to facilitate growth
- 7.2.1.4 Other PCR-based molecular assays
- 7.2.1.1 Sequence-specific primer-PCR
- 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
- 7.2.2.1 Sanger sequencing
- 7.2.2.1.1 Increasing use of sanger sequencing in clinical settings for organ and bone marrow transplantations to aid growth
- 7.2.2.2 Next-generation sequencing
- 7.2.2.2.1 Growing reliance on outsourcing to fuel market
- 7.2.2.3 Other sequencing-based molecular assays
- 7.2.2.1 Sanger sequencing
- 7.2.1 PCR-BASED MOLECULAR ASSAYS
- 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
- 7.3.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO AUGMENT GROWTH
8 HLA TYPING MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 DIAGNOSTIC APPLICATIONS
- 8.2.1 DONOR-RECIPIENT CROSS-MATCHING
- 8.2.1.1 Increasing focus on successful organ transplants to foster growth
- 8.2.2 INFECTIOUS DISEASE TESTING
- 8.2.2.1 Rising prevalence of infectious diseases to accelerate growth
- 8.2.3 CANCER DIAGNOSTIC & PREVENTION
- 8.2.3.1 Increasing demand for accurate and early cancer diagnosis to bolster growth
- 8.2.4 TRANSFUSION THERAPY
- 8.2.4.1 Growing clinical evidence supporting hla typing to propel market
- 8.2.5 OTHER DIAGNOSTIC APPLICATIONS
- 8.2.1 DONOR-RECIPIENT CROSS-MATCHING
- 8.3 RESEARCH APPLICATIONS
- 8.3.1 EXPANDING USE OF GENOMIC TECHNOLOGIES TO EXPEDITE GROWTH
9 HLA TYPING MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 COMMERCIAL SERVICE PROVIDERS
- 9.2.1 RISING DEMAND FOR OUTSOURCED SERVICES TO CONTRIBUTE TO GROWTH
- 9.3 HOSPITALS & TRANSPLANT CENTERS
- 9.3.1 GROWING DEMAND FOR ORGAN TRANSPLANTS TO BOOST MARKET
- 9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
- 9.4.1 INCREASING RESEARCH ACTIVITIES TO PROMOTE GROWTH
10 HLA TYPING MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 10.2.2 US
- 10.2.2.1 Expanding donor registries and precision medicine to propel market
- 10.2.3 CANADA
- 10.2.3.1 Evolving healthcare landscape to augment growth
- 10.3 EUROPE
- 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 10.3.2 GERMANY
- 10.3.2.1 Growing investments in genomic research and digital healthcare to drive market
- 10.3.3 UK
- 10.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth
- 10.3.4 FRANCE
- 10.3.4.1 Growing adoption for donor-recipient compatibility testing to boost market
- 10.3.5 SPAIN
- 10.3.5.1 Increasing solid organ transplantation procedures to facilitate growth
- 10.3.6 ITALY
- 10.3.6.1 Supportive government policies and strong healthcare infrastructure to promote growth
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 10.4.2 CHINA
- 10.4.2.1 Increasing utilization of hla typing for donor-recipient matching to propel market
- 10.4.3 JAPAN
- 10.4.3.1 Growing burden of chronic diseases to boost market
- 10.4.4 INDIA
- 10.4.4.1 Increasing government efforts to offer free access to support growth
- 10.4.5 SOUTH KOREA
- 10.4.5.1 Advanced healthcare to contribute to growth
- 10.4.6 AUSTRALIA
- 10.4.6.1 Increasing integration of genomic tools in diagnostics to promote growth
- 10.4.7 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 10.5.2 BRAZIL
- 10.5.2.1 Growing adoption of next-generation sequencing to drive market
- 10.5.3 MEXICO
- 10.5.3.1 Supportive business environment to bolster growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 10.6.2 GCC COUNTRIES
- 10.6.2.1 Improvements in healthcare infrastructure to spur growth
- 10.6.3 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGIES
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HLA TYPING MARKET
- 11.3 REVENUE ANALYSIS, 2020-2024
- 11.4 MARKET SHARE ANALYSIS, 2024
- 11.5 COMPANY VALUATION AND FINANCIAL METRICS
- 11.6 PRODUCT/BRAND COMPARISON
- 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 11.7.1 STARS
- 11.7.2 EMERGING LEADERS
- 11.7.3 PERVASIVE PLAYERS
- 11.7.4 PARTICIPANTS
- 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 11.7.5.1 Company footprint
- 11.7.5.2 Region footprint
- 11.7.5.3 Product footprint
- 11.7.5.4 Technology footprint
- 11.7.5.5 Application footprint
- 11.7.5.6 End-user footprint
- 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 11.8.1 PROGRESSIVE COMPANIES
- 11.8.2 RESPONSIVE COMPANIES
- 11.8.3 DYNAMIC COMPANIES
- 11.8.4 STARTING BLOCKS
- 11.8.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024
- 11.8.5.1 Detailed list of key startup/sme players
- 11.8.5.2 Competitive benchmarking of startups/smes
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES AND APPROVALS
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
12 COMPANY PROFILES
- 12.1 MAJOR PLAYER
- 12.1.1 BD
- 12.1.1.1 Business overview
- 12.1.1.2 Products offered
- 12.1.1.3 Mnm view
- 12.1.1.3.1 Key Strengths
- 12.1.1.3.2 Strategic choices
- 12.1.1.3.3 Weaknesses and competitive threats
- 12.1.2 THERMO FISHER SCIENTIFIC INC.
- 12.1.2.1 Business overview
- 12.1.2.2 Products offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches and approvals
- 12.1.2.3.2 Deals
- 12.1.2.3.3 Expansions
- 12.1.2.4 Mnm view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 ILLUMINA, INC.
- 12.1.3.1 Business overview
- 12.1.3.2 Products offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Expansions
- 12.1.3.4 Mnm view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 QIAGEN
- 12.1.4.1 Business overview
- 12.1.4.2 Products offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Product launches and approvals
- 12.1.4.3.2 Deals
- 12.1.4.4 Mnm view
- 12.1.4.4.1 Key strengths
- 12.1.4.4.2 Strategic choices
- 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 BIO-RAD LABORATORIES, INC.
- 12.1.5.1 Business overview
- 12.1.5.2 Products offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Product launches and approvals
- 12.1.5.4 Mnm view
- 12.1.5.4.1 Key strengths
- 12.1.5.4.2 Strategic choices
- 12.1.5.4.3 Weaknesses and competitive threats
- 12.1.6 F. HOFFMANN-LA ROCHE LTD
- 12.1.6.1 Business overview
- 12.1.6.2 Products offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Product launches and approvals
- 12.1.6.3.2 Expansions
- 12.1.6.4 Mnm view
- 12.1.6.4.1 Key strengths
- 12.1.6.4.2 Strategic choices
- 12.1.6.4.3 Weaknesses and competitive threats
- 12.1.7 CAREDX, INC.
- 12.1.7.1 Business overview
- 12.1.7.2 Products offered
- 12.1.7.3 Recent developments
- 12.1.7.3.1 Product launches and approvals
- 12.1.7.3.2 Deals
- 12.1.8 WERFEN
- 12.1.8.1 Business overview
- 12.1.8.2 Products offered
- 12.1.8.3 Recent developments
- 12.1.8.3.1 Product launches and approvals
- 12.1.8.3.2 Deals
- 12.1.9 DIASORIN S.P.A.
- 12.1.9.1 Business overview
- 12.1.9.2 Products offered
- 12.1.9.3 Recent developments
- 12.1.9.3.1 Product launches and approvals
- 12.1.10 TBG BIOTECHNOLOGY CORPORATION
- 12.1.10.1 Business overview
- 12.1.10.2 Products offered
- 12.1.10.3 Recent developments
- 12.1.10.3.1 Product launches and approvals
- 12.1.10.3.2 Deals
- 12.1.11 FUJIREBIO
- 12.1.11.1 Business overview
- 12.1.11.2 Products offered
- 12.1.11.3 Recent developments
- 12.1.11.3.1 Deals
- 12.1.12 EUROBIO SCIENTIFIC
- 12.1.12.1 Business overview
- 12.1.12.2 Products offered
- 12.1.12.3 Recent developments
- 12.1.12.3.1 Product launches and approvals
- 12.1.12.3.2 Deals
- 12.1.13 PACBIO
- 12.1.13.1 Business overview
- 12.1.13.2 Products offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Product launches and approvals
- 12.1.13.3.2 Deals
- 12.1.14 BAG DIAGNOSTICS GMBH
- 12.1.14.1 Business overview
- 12.1.14.2 Products offered
- 12.1.15 CREATIVE BIOLABS
- 12.1.15.1 Business overview
- 12.1.15.2 Products offered
- 12.1.1 BD
- 12.2 OTHER PLAYERS
- 12.2.1 HISTOGENETICS LLC
- 12.2.2 SCISCO GENETICS, INC.
- 12.2.3 INNO-TRAIN DIAGNOSTIK GMBH
- 12.2.4 BIONOBIS
- 12.2.5 TAKARA BIO INC.
- 12.2.6 KRISHGEN BIOSYSTEMS
- 12.2.7 SCIENCELL RESEARCH LABORATORIES, INC.
- 12.2.8 PROIMMUNE LTD.
- 12.2.9 BIOFORTUNA LIMITED
- 12.2.10 ALPHA BIOTECH LIMITED
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
Product Code: MD 7576
List of Tables
- TABLE 1 HLA TYPING MARKET: INCLUSIONS AND EXCLUSIONS
- TABLE 2 HLA TYPING MARKET: RISK ANALYSIS
- TABLE 3 HLA TYPING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
- TABLE 4 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS, 2024 (USD)
- TABLE 5 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022-2024
- TABLE 6 HLA TYPING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- TABLE 7 HLA TYPING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024-2025
- TABLE 8 IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
- TABLE 9 EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020-2024 (USD THOUSAND)
- TABLE 10 HLA TYPING MARKET KEY CONFERENCES AND EVENTS, 2025-2026
- TABLE 11 DEVELOPMENT AND IMPLEMENTATION OF INFORMATION SYSTEM FOR HLA TYPING LABORATORY MANAGEMENT
- TABLE 12 IMPROVED HLA TYPING ACCURACY ACROSS DIVERSE SAMPLE TYPES USING SEQUENCING-BASED ASSAYS
- TABLE 13 HIGH-RESOLUTION EXTENDED 6-LOCI HLA TYPING FOR IDENTIFYING RELATED DONORS IN INDIAN SUBCONTINENT
- TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 18 HLA TYPING MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
- TABLE 20 KEY BUYING CRITERIA FOR END USERS
- TABLE 21 HLA TYPING MARKET: UNMET NEEDS
- TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 23 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 24 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 25 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 26 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 27 HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 28 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 29 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 30 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 31 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 32 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 33 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 34 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2023-2030 (USD MILLION)
- TABLE 35 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 36 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 37 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 38 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
- TABLE 39 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
- TABLE 40 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 41 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 42 HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 43 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 44 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 45 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2023-2030 (USD MILLION)
- TABLE 46 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2023-2030 (USD MILLION)
- TABLE 47 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2023-2030 (USD MILLION)
- TABLE 48 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2023-2030 (USD MILLION)
- TABLE 49 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 50 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 51 HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 52 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 53 HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 54 HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 55 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS)
- TABLE 56 NORTH AMERICA: TRANSPLANT VOLUME, 2024
- TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 58 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 59 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 60 NORTH AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 61 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 62 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 63 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 64 NORTH AMERICA: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 65 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 66 US: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 67 US: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 68 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 69 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 70 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 71 CANADA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 72 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 73 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 74 EUROPE: TRANSPLANT VOLUME, 2024
- TABLE 75 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 76 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 77 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 78 EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 79 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 80 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 81 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 82 EUROPE: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 83 EUROPE: HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 84 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 85 GERMANY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 86 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 87 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 88 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 89 UK: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 90 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 91 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 93 FRANCE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 94 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 95 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 96 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 97 SPAIN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 98 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 99 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 100 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 101 ITALY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 102 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 103 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 104 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 105 REST OF EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 106 REST OF EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 107 REST OF EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 108 ASIA PACIFIC: TRANSPLANT VOLUME, 2024
- TABLE 109 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 110 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 111 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 112 ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 113 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 114 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 115 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 116 ASIA PACIFIC: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 117 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 118 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 119 CHINA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 120 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 121 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 122 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 123 JAPAN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 124 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 125 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 126 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 127 INDIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 128 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 129 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 130 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 131 SOUTH KOREA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 132 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 133 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 134 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 135 AUSTRALIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 136 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 137 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 138 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 139 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 140 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 141 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 142 LATIN AMERICA: TRANSPLANT VOLUME, 2024
- TABLE 143 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 144 LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 145 LATIN AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 146 LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 147 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 148 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 149 LATIN AMERICA: HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 150 LATIN AMERICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION, 2023-2030 (USD MILLION)
- TABLE 151 LATIN AMERICA: HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 152 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 153 BRAZIL: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 154 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 155 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 156 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 157 MEXICO: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 158 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 159 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 160 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 161 REST OF LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 162 REST OF LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 163 REST OF LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 164 MIDDLE EAST & AFRICA: TRANSPLANT VOLUME, 2024
- TABLE 165 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 166 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 167 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
- TABLE 168 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 169 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 170 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 171 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
- TABLE 172 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION, 2023-2030 (USD MILLION)
- TABLE 173 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 174 GCC COUNTRIES: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 175 GCC COUNTRIES: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 176 GCC COUNTRIES: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 177 GCC COUNTRIES: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 178 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
- TABLE 179 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 180 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 181 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 182 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN HLA TYPING MARKET
- TABLE 183 HLA TYPING MARKET: DEGREE OF COMPETITION
- TABLE 184 HLA TYPING MARKET: REGION FOOTPRINT
- TABLE 185 HLA TYPING MARKET: PRODUCT & SERVICE FOOTPRINT
- TABLE 186 HLA TYPING MARKET: TECHNOLOGY FOOTPRINT
- TABLE 187 HLA TYPING MARKET: APPLICATION FOOTPRINT
- TABLE 188 HLA TYPING MARKET: END-USER FOOTPRINT
- TABLE 189 HLA TYPING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
- TABLE 190 HLA TYPING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
- TABLE 191 HLA TYPING MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-APRIL 2025
- TABLE 192 HLA TYPING MARKET: DEALS, JANUARY 2021-APRIL 2025
- TABLE 193 HLA TYPING MARKET: EXPANSIONS, JANUARY 2021-APRIL 2025
- TABLE 194 BD: COMPANY OVERVIEW
- TABLE 195 BD: PRODUCTS OFFERED
- TABLE 196 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
- TABLE 197 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
- TABLE 198 THERMO FISHER SCIENTIFIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 199 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-APRIL 2025
- TABLE 200 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
- TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW
- TABLE 202 ILLUMINA, INC.: PRODUCTS OFFERED
- TABLE 203 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
- TABLE 204 QIAGEN: COMPANY OVERVIEW
- TABLE 205 QIAGEN: PRODUCTS OFFERED
- TABLE 206 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 207 QIAGEN: DEALS, JANUARY 2021-APRIL 2025
- TABLE 208 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 209 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
- TABLE 210 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 211 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
- TABLE 212 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
- TABLE 213 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 214 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021-APRIL 2025
- TABLE 215 CAREDX, INC.: COMPANY OVERVIEW
- TABLE 216 CAREDX, INC.: PRODUCTS OFFERED
- TABLE 217 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 218 CAREDX, INC.: DEALS, JANUARY 2022-APRIL 2025
- TABLE 219 WERFEN: COMPANY OVERVIEW
- TABLE 220 WERFEN: PRODUCTS OFFERED
- TABLE 221 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 222 WERFEN: DEALS, JANUARY 2022-APRIL 2025
- TABLE 223 DIASORIN S.P.A.: COMPANY OVERVIEW
- TABLE 224 DIASORIN S.P.A.: PRODUCTS OFFERED
- TABLE 225 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 226 TBG BIOTECHNOLOGY CORPORATION: COMPANY OVERVIEW
- TABLE 227 TBG BIOTECHNOLOGY CORPORATION: PRODUCTS OFFERED
- TABLE 228 TBG BIOTECHNOLOGY CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 229 TBG BIOTECHNOLOGY CORPORATION: DEALS, JANUARY 2022-APRIL 2025
- TABLE 230 FUJIREBIO: COMPANY OVERVIEW
- TABLE 231 FUJIREBIO: PRODUCTS OFFERED
- TABLE 232 FUJIREBIO: DEALS, JANUARY 2022-APRIL 2025
- TABLE 233 EUROBIO SCIENTIFIC.: COMPANY OVERVIEW
- TABLE 234 EUROBIO SCIENTIFIC: PRODUCTS OFFERED
- TABLE 235 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 236 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022-APRIL 2025
- TABLE 237 PACBIO: COMPANY OVERVIEW
- TABLE 238 PACBIO: PRODUCTS OFFERED
- TABLE 239 PACBIO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
- TABLE 240 PACBIO: DEALS, JANUARY 2022-APRIL 2025
- TABLE 241 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
- TABLE 242 BAG DIAGNOSTICS GMBH: PRODUCTS OFFERED
- TABLE 243 CREATIVE BIOLABS: COMPANY OVERVIEW
- TABLE 244 CREATIVE BIOLABS: PRODUCTS OFFERED
- TABLE 245 HISTOGENETICS LLC: COMPANY OVERVIEW
- TABLE 246 SCISCO GENETICS, INC.: COMPANY OVERVIEW
- TABLE 247 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
- TABLE 248 BIONOBIS: COMPANY OVERVIEW
- TABLE 249 TAKARA BIO INC.: COMPANY OVERVIEW
- TABLE 250 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW
- TABLE 251 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 252 PROIMMUNE LTD.: COMPANY OVERVIEW
- TABLE 253 BIOFORTUNA LIMITED: COMPANY OVERVIEW
- TABLE 254 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW
List of Figures
- FIGURE 1 HLA TYPING MARKET SEGMENTATION AND REGIONAL SCOPE
- FIGURE 2 HLA TYPING MARKET: YEARS CONSIDERED
- FIGURE 3 HLA TYPING MARKET: RESEARCH DESIGN
- FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
- FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024
- FIGURE 7 HLA TYPING MARKET: MARKET SIZE ESTIMATION METHODOLOGY
- FIGURE 8 HLA TYPING MARKET: GROWTH PROJECTIONS BASED ON REVENUE IMPACT OF KEY MACRO INDICATORS
- FIGURE 9 DATA TRIANGULATION
- FIGURE 10 RESEARCH LIMITATIONS
- FIGURE 11 HLA TYPING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
- FIGURE 12 HLA TYPING MARKET, BY PRODUCT &SERVICES, 2025 VS. 2030 (USD MILLION)
- FIGURE 13 HLA TYPING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
- FIGURE 14 HLA TYPING MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
- FIGURE 15 GEOGRAPHIC SNAPSHOT OF HLA TYPING MARKET
- FIGURE 16 GROWING NUMBER OF ORGAN TRANSPLANT PROCEDURES TO DRIVE MARKET
- FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
- FIGURE 18 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- FIGURE 20 AVERAGE SELLING PRICE OF INSTRUMENTS, 2024 (USD THOUSAND)
- FIGURE 21 AVERAGE SELLING PRICE OF REAGENTS, 2024 (USD THOUSAND)
- FIGURE 22 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD THOUSAND)
- FIGURE 23 HLA TYPING MARKET: VALUE CHAIN ANALYSIS
- FIGURE 24 HLA TYPING MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 25 HLA TYPING MARKET: ECOSYSTEM ANALYSIS
- FIGURE 26 INVESTMENTS AND FUNDING SCENARIO, 2019-2023
- FIGURE 27 NUMBER OF DEALS IN MARKET, BY KEY PLAYER, 2019-2023
- FIGURE 28 VALUE OF DEALS IN MARKET, BY KEY PLAYER, 2019-2023 (USD)
- FIGURE 29 HLA TYPING MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
- FIGURE 30 HLA TYPING MARKET: IMPORT SCENARIO FOR HS CODE 3822, 2020-2024
- FIGURE 31 HLA TYPING MARKET: EXPORT SCENARIO FOR HS CODE 3822, 2020-2024
- FIGURE 32 HLA TYPING MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
- FIGURE 34 KEY BUYING CRITERIA FOR END USERS
- FIGURE 35 NORTH AMERICA: HLA TYPING MARKET SNAPSHOT
- FIGURE 36 ASIA: HLA TYPING MARKET SNAPSHOT
- FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING MARKET, 2020-2024
- FIGURE 38 HLA TYPING MARKET SHARE ANALYSIS, 2024
- FIGURE 39 EV/EBITDA OF KEY VENDORS
- FIGURE 40 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 41 HLA TYPING MARKET: PRODUCT/BRAND COMPARISON
- FIGURE 42 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- FIGURE 43 HLA TYPING MARKET: COMPANY FOOTPRINT
- FIGURE 44 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
- FIGURE 45 BD: COMPANY SNAPSHOT (2024)
- FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
- FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2024)
- FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
- FIGURE 51 CAREDX, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 52 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024)
- FIGURE 53 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT (2024)
- FIGURE 54 PACBIO: COMPANY SNAPSHOT (2022)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.